Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Geron Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 30, 2012 • 1 Comment
-
-
-
-
-
-
-
-
-
-
-
-
-
Geron Q2 Results: Net Loss of $21.1 MillionHenry McCusker • Mon, Aug 1, 2011
-
-
-
-
-
-
-
-
Geron Management Discusses Q3 2012 Results - Earnings Call TranscriptTue, Oct 30, 2012 • 1 Comment
-
Geron Management Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 1 Comment
-
Geron CEO Discusses Q3 2010 Results - Earnings Call TranscriptSat, Oct 30, 2010 • 2 Comments
-
Geron Corporation Q2 2010 Earnings Call TranscriptSat, Jul 31, 2010
-
Geron Corporation Q1 2010 Earnings Call TranscriptSun, Jun 13, 2010 • 7 Comments
-
Geron Corporation Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
Geron Corporation Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008 • 2 Comments
-
at CNBC.com (Jan 17, 2013)
-
at MarketWatch.com (Dec 3, 2012)
-
at CNBC.com (Dec 3, 2012)
-
at MarketWatch.com (Sep 10, 2012)
-
at CNBC.com (Sep 10, 2012)
-
at MarketWatch.com (Aug 30, 2012)
-
at MarketWatch.com (Aug 30, 2012)
-
Business Wire (Dec 12, 2011)
-
at MarketWatch.com (Nov 15, 2011)
-
at MarketWatch.com (Sep 30, 2011)
-
at MarketWatch.com (Jul 13, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at MarketWatch.com (Jul 8, 2011)
-
at CNBC.com (Jun 27, 2011)
-
at MarketWatch.com (May 2, 2011)
-
at MarketWatch.com (Mar 14, 2011)
-
at CNBC.com (Jan 26, 2011)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Oct 11, 2010)
GERN vs. ETF Alternatives
Company Description
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple... More
